WHO IS THE APPROPRIATE PATIENT FOR GLP-1 RAS? (AS-111)

Saturday, October 28, 2023

12:30 – 13:30 EST

Location: Palais, 517BC

Target Audience: Cardiologists, Endocrinologists, Diabetologists

Chair : AS(s)

Kim A. Connelly, MBBS, PhD (he/him/his)

Executive Director, Keenan Research Center & Division Head, Cardiology
St.Michael's Hospital, Unity Health Toronto
University of Toronto

Presenter : AS(s)

Heidi Dutton

MD, MSc, FRCPC, Dipl. ABOM & ABLM
The Ottawa Hospital
University of Ottawa
Sarah Moore-Vasram, BScN, MN, PhD, RN(EC)-Adult (she/her/hers)

Academic Clinician, Nursing Research Lead
Providence Care Hospital
Queen's University
Sonja M. Reichert, MD, MSc, CCFP, ABOM Diplomate (she/her/hers)

Family Physician, Associate Professor, Clinician Researcher
St. Joseph's Primary Care Diabetes Support Program, Western University
Western University
MT

Michael A. Tsoukas, MD

Disclosure(s):

Kim A. Connelly, MBBS, PhD: Abbott: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); AstraZeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); NovoNordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Servier: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

recognize patient profiles where introduction of GLP-1 RA therapy would be appropriate to reduce the risk of diabetes-related complications;
discuss the latest evidence in conjunction with clinical practical guidelines (Canadian Cardiovascular Society Guidelines and Diabetes Canada Clinical practice Guidelines) to provide rationale for early initiation of GLP-1 RAs in patients with type 2 diabetes; and
identify clinical complexities and barriers in the initiation and use of GLP-1 RAs and examine solutions through interdisciplinary perspectives.

This program was co-developed by the Canadian Society of Endocrinology and Metabolism and Novo Nordisk Canada and was planned to achieve scientific integrity, objectivity, and balance.